Table of Contents
Chapter 1. Executive Summary
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.3 Assumptions
2.4 Limitations
Chapter 3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
Chapter 4. Market Dynamics
4.1 Overview
4.2 Drivers
4.3 Restraints
4.4 Opportunities
4.5 Pipeline Analysis
4.5 Macroeconomic Indicators
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Opportunities
Chapter 6. Global Myelodysplastic Syndrome (MDS) Drugs Market, by Type
6.1 Overview
6.2 Chemotherapy
6.2.1 Hypomethylating Drugs
6.2.1.1 Azacitidine
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.1.2 Decitabine
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.2 Conventional Drugs
6.2.2.1 Cytarabine
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.2.2 Daunorubicin
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.2.3 Idarubicin
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3 Immunomodulatory Drugs
6.3.1 Lenalidomide
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3.2 Thalidomide
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4 Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
Chapter 7. Global Myelodysplastic Syndrome (MDS) Drugs Market, by Type of Syndrome
7.1 Overview
7.2 Refractory Anemia
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3 Refractory Anemia with Ringed Sideroblasts
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4 Refractory Anemia with Excess Blasts
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.5 Refractory Cytopenia with Multilineage Dysplasia
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.6 Other
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
Chapter 8. Global Myelodysplastic Syndrome (MDS) Drugs Market, by Route of Administration
8.1 Overview
8.2 Oral
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.3 Parenteral
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.4 Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
Chapter 9. Global Myelodysplastic Syndrome (MDS) Drugs Market, by End User
9.1 Overview
9.2 Hospitals
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9.3 Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9.4 Ambulatory Surgical Centers
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9.5 Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
Chapter 10. Global Myelodysplastic Syndrome (MDS) Drugs Market, by Region
10.1 Overview
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
Chapter 11. Company Landscape
11.1 Overview
11.2 Market Share Analysis
11.3 Key Development & Strategies
Chapter 12 Company Profiles
12.1 BluePoint Laboratories
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials Overview
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.1.6 Key Strategies
12.2 Celgene Corporation
12.3 Cipla USA Inc
12.4 Dr. Reddy's Laboratories Inc
12.5 Fosun Pharma Industrial Pte. Ltd.
12.6 Hikma Pharmaceuticals PLC
12.7 Jazz Pharmaceuticals, Inc.
12.8 Johnson & Johnson
12.9 Lupin Ltd
12.10 Otsuka America Pharmaceutical, Inc
12.11 Pfizer
12.12 Sandoz
12.13 Shilpa Medicare Limited
12.14 Sun Pharmaceutical Industries, Inc
12.15 Teva Pharmaceutical Industries Ltd
12.16 Others
Chapter 13 Appendix
LIST OF TABLES
TABLE 1. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SYNOPSIS, 2020-2027
TABLE 2. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET ESTIMATES AND FORECAST, 2020-2027 (USD MILLION)
TABLE 3. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 4. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 5. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)
TABLE 6. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
TABLE 7. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 8. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 9. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)
TABLE 10. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
TABLE 11. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 12. US: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 13. US: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)
TABLE 14. US: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
TABLE 15. US: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 16. CANADA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 17. CANADA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)
TABLE 18. CANADA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
TABLE 19. CANADA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 20. LATIN AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 21. LATIN AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)
TABLE 22. LATIN AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
TABLE 23. LATIN AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 24. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 25. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)
TABLE 26. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
TABLE 27. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 28. WESTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 29. WESTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)
TABLE 30. WESTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
TABLE 31. WESTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 32. EASTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 33. EASTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)
TABLE 34. EASTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
TABLE 35. EASTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 36. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 37. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)
TABLE 38. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
TABLE 39. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 40. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 41. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)
TABLE 42. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
TABLE 43. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1. RESEARCH PROCESS
FIGURE 2. SEGMENTATION FOR GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET
FIGURE 3. MARKET DYNAMICS FOR GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET
FIGURE 4. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY TYPE, 2020
FIGURE 5. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY TYPE OF SYNDROME, 2020
FIGURE 6. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION
FIGURE 7. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY END USER, 2020
FIGURE 8. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY REGION, 2020
FIGURE 9. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY COUNTRY, 2020
FIGURE 10. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY COUNTRY, 2020
FIGURE 11. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY COUNTRY, 2020
FIGURE 12. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY REGION, 2020
FIGURE 13. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 14. BLUEPOINT LABORATORIES: KEY FINANCIALS
FIGURE 15. BLUEPOINT LABORATORIES: SEGMENTAL REVENUE
FIGURE 16. BLUEPOINT LABORATORIES: GEOGRAPHICAL REVENUE
FIGURE 17. CELGENE CORPORATION: KEY FINANCIALS
FIGURE 18. CELGENE CORPORATION: SEGMENTAL REVENUE
FIGURE 19. CELGENE CORPORATION: GEOGRAPHICAL REVENUE
FIGURE 20. CELGENE EUROPE LIMITED: KEY FINANCIALS
FIGURE 21. CELGENE EUROPE LIMITED: SEGMENTAL REVENUE
FIGURE 22. CELGENE EUROPE LIMITED: GEOGRAPHICAL REVENUE
FIGURE 23. CIPLA USA INC: KEY FINANCIALS
FIGURE 24. CIPLA USA INC: SEGMENTAL REVENUE
FIGURE 25. CIPLA USA INC: GEOGRAPHICAL REVENUE
FIGURE 26. DR. REDDY’S LABORATORIES INC: KEY FINANCIALS
FIGURE 27. DR. REDDY’S LABORATORIES INC: SEGMENTAL REVENUE
FIGURE 28. DR. REDDY’S LABORATORIES INC: GEOGRAPHICAL REVENUE
FIGURE 29. FOSUN PHARMA INDUSTRIAL PTE. LTD.: KEY FINANCIALS
FIGURE 30. FOSUN PHARMA INDUSTRIAL PTE. LTD.: SEGMENTAL REVENUE
FIGURE 31. FOSUN PHARMA INDUSTRIAL PTE. LTD.: GEOGRAPHICAL REVENUE
FIGURE 32. HIKMA PHARMACEUTICALS PLC: KEY FINANCIALS
FIGURE 33. PHARMACEUTICALS PLC: SEGMENTAL REVENUE
FIGURE 34. HIKMA PHARMACEUTICALS PLC: GEOGRAPHICAL REVENUE
FIGURE 35. JAZZ PHARMACEUTICALS, INC: KEY FINANCIALS
FIGURE 36. JAZZ PHARMACEUTICALS, INC: SEGMENTAL REVENUE
FIGURE 37. JAZZ PHARMACEUTICALS, INC: GEOGRAPHICAL REVENUE
FIGURE 38. JOHNSON & JOHNSON: KEY FINANCIALS
FIGURE 39. JOHNSON & JOHNSON: SEGMENTAL REVENUE
FIGURE 40. JOHNSON & JOHNSON: GEOGRAPHICAL REVENUE
FIGURE 41. LUPIN LTD: KEY FINANCIALS
FIGURE 42. LUPIN LTD: SEGMENTAL REVENUE
FIGURE 43. LUPIN LTD: GEOGRAPHICAL REVENUE
FIGURE 44. OTSUKA AMERICA PHARMACEUTICAL, INC: KEY FINANCIALS
FIGURE 45. OTSUKA AMERICA PHARMACEUTICAL, INC: SEGMENTAL REVENUE
FIGURE 46. OTSUKA AMERICA PHARMACEUTICAL, INC: GEOGRAPHICAL REVENUE
FIGURE 47. PFIZER: KEY FINANCIALS
FIGURE 48. PFIZER: SEGMENTAL REVENUE
FIGURE 49. PFIZER: GEOGRAPHICAL REVENUE
FIGURE 50. SANDOZ: KEY FINANCIALS
FIGURE 51. SANDOZ: SEGMENTAL REVENUE
FIGURE 52. SANDOZ: GEOGRAPHICAL REVENUE
FIGURE 53. SHILPA MEDICARE LIMITED: KEY FINANCIALS
FIGURE 54. SHILPA MEDICARE LIMITED: SEGMENTAL REVENUE
FIGURE 55. SHILPA MEDICARE LIMITED: GEOGRAPHICAL REVENUE
FIGURE 56. SUN PHARMACEUTICAL INDUSTRIES, INC: KEY FINANCIALS
FIGURE 57. SUN PHARMACEUTICAL INDUSTRIES, INC: SEGMENTAL REVENUE
FIGURE 58. SUN PHARMACEUTICAL INDUSTRIES, INC: GEOGRAPHICAL REVENUE
FIGURE 59. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS
FIGURE 60. TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE
FIGURE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL REVENUE
